APOA2 Genotype

Two people can eat the same buttery, fatty meals for years and walk away with very different waistlines. Part of the reason sits inside a small gene called APOA2, which carries instructions for one of the proteins that rides inside your HDL (high-density lipoprotein, the so-called good cholesterol). A common inherited change in this gene can make your body behave differently when saturated fat shows up at dinner.

This is a one-time DNA test. The result does not change over your lifetime, but what it tells you can quietly steer decisions about diet, weight, and metabolic risk for decades. It is most useful if you have struggled with stubborn weight, eat a typical Western diet rich in saturated fat, or want to understand why standard lipid numbers do not fully explain your appetite or body weight.

What This Test Looks At

The APOA2 (apolipoprotein A-II) gene sits on chromosome 1 and codes for the second most abundant protein on HDL particles. The protein is made almost entirely in the liver in humans, and it helps shape how HDL is built, remodeled, and how it carries cholesterol around the body.

Most APOA2 testing focuses on a common single-letter change in the gene's regulatory region known as -265T>C (also written as -256T>C, or rs5082, in some papers due to differences in numbering conventions). Think of the regulatory region as the dimmer switch that controls how much APOA2 protein the liver makes. Carrying one or two copies of the C version of this switch is linked to different protein output, and to differences in appetite, body weight, and metabolic markers, particularly when the diet is high in saturated fat.

Body Weight and Appetite

In a study of 1,078 adults from the Genetics of Lipid Lowering Drugs and Diet Network, people who carried two copies of the C version (CC genotype) had a higher body mass index than people carrying at least one T copy, and they reported eating more total calories, fat, and protein each day. The odds of being obese were roughly 70 percent higher in CC carriers compared with T-allele carriers (odds ratio about 1.7).

A larger replication study in 4,602 adults from Mediterranean and Asian populations confirmed an interaction between APOA2 genotype and saturated fat intake on body weight, suggesting this is not a quirk of one population. Other work has linked the same variant to differences in eating behavior and in ghrelin, the hormone that signals hunger, hinting at a mechanism that runs through appetite regulation.

The Saturated Fat Connection

The body weight effect is not the same for everyone with the CC genotype. It shows up most clearly in people who eat a lot of saturated fat. In a multi-stage epigenomics and metabolomics study (an initial scan in 80 adults, validated in two larger cohorts of 379 and 243 adults), CC carriers eating a high-saturated-fat diet had lower APOA2 gene activity in their cells, distinct chemical tags on the gene's regulatory region, and altered handling of certain amino acids (the branched-chain amino acids and tryptophan) that have been linked to insulin resistance.

The practical read: this is a gene-diet variant. If your genotype is CC and your diet is rich in butter, fatty meats, cream, and processed foods high in saturated fat, your biology appears to respond differently than a TT carrier eating the same plate. The genotype is fixed. The diet is not.

Cardiometabolic and Diabetes Risk

In a cross-sectional study of 737 adults with type 2 diabetes, carriers of at least one C allele had higher triglycerides, higher levels of the hunger hormone ghrelin, and higher high-sensitivity C-reactive protein (a marker of low-grade inflammation, often shortened to hs-CRP) than people with two T copies. These differences were most pronounced in participants who also had a high dietary acid load, a pattern produced by eating a lot of animal protein and refined grains with few fruits and vegetables.

A separate analysis of 700 adults with type 2 diabetes built a multi-variant genetic risk score that included rs5082 and found a meaningful link to higher BMI, larger waist circumference, higher hs-CRP, and lower levels of antioxidant markers. Because rs5082 was just one of several variants in that score, those findings reflect the composite signal rather than APOA2 alone. Still, the work places the C allele inside a broader pattern of metabolic and inflammatory risk worth paying attention to, especially in people already managing prediabetes or type 2 diabetes.

Response to Weight-Loss Programs

Your genotype may also shape how well certain interventions work for you. In a digital cognitive behavioral therapy program for obesity tested in 45 adults, people carrying the G allele at rs5082 (an alternate way of labeling the same variant) showed an increasing trend in BMI and weight during the program, while AA carriers lost weight and body fat. The sample is small, so treat this as an early signal rather than a settled finding, but it points to the idea that a one-size-fits-all weight-loss program may not behave the same way in every APOA2 genotype.

Rare Variants and Serious Disease

Beyond the common promoter variant, the APOA2 gene can also carry rare changes that disrupt the normal stop signal at the end of the protein. These rare stop-codon mutations create an unusually long version of the apoA-II protein that can clump together and form deposits in the kidney, leading to a hereditary form of organ damage called systemic amyloidosis. These mutations are exceedingly rare and are typically detected only in families with a known history of unexplained kidney failure or amyloid disease, not in routine APOA2 panels.

Separately, in two cohorts totaling 1,161 adults with septic shock, a different APOA2 variant called rs6413453 was associated with higher 28-day mortality and more organ dysfunction in carriers of the GG genotype, with genetic analyses suggesting that lower apoA-II protein levels may causally raise the risk of dying from sepsis. This is relevant for understanding the protein's biology but does not translate into a routine reason to test in healthy adults.

Reconciling the Mixed Picture

APOA2 evidence can feel contradictory. Depending on the population and the dietary context studied, the C allele has been linked to higher BMI, more eating, and more inflammation in some settings and to less consistent or even opposing patterns in others. The unifying framework is that APOA2 is not a simple good number, bad number marker. It is a phenotype indicator, meaning it shapes how your body responds to inputs like saturated fat, dietary acid load, and weight-loss programs. The same genotype can look protective in one dietary context and harmful in another. That is why the genotype is most useful as a guide to behavior, not as a standalone risk score.

What an Unexpected Result Should Prompt

If your APOA2 result shows the CC (or G/G) genotype, the most useful next move is to look honestly at your saturated fat intake and to bring your standard cardiometabolic numbers into focus. Order a comprehensive metabolic panel, a lipid panel that includes ApoB (apolipoprotein B, the best single marker of atherogenic particle count), HbA1c (hemoglobin A1c, a three-month average of blood sugar), fasting insulin, and hs-CRP. Pair the genotype with these phenotype tests at least annually so you can watch how the markers respond as you adjust your diet.

If you carry a rare APOA2 variant flagged on a broader sequencing panel, particularly one near the stop codon, and you have a family history of unexplained kidney disease or amyloidosis, a referral to a medical geneticist or nephrologist is appropriate. For the common -265T>C variant, the action lives in your kitchen and your annual labs, not in repeat genetic testing.

One-Time Result, Lifetime Use

This is a one-time test. Your APOA2 genotype is set at conception and will not change. There is no value in retesting the gene itself unless your variant call confidence is in question or a different testing method is needed to confirm a rare variant. The ongoing value comes from using the result to drive years of dietary decisions and from tracking the downstream metabolic markers that actually move: weight, waist, ApoB, triglycerides, HbA1c, fasting insulin, and hs-CRP. A reasonable rhythm is to check those companion markers at baseline, again in three to six months after any major diet change, and at least annually thereafter.